Ionis's Zilganersen Becomes First Drug to Show Disease-Modifying Effect in Alexander Disease as FDA Sets September Decision
An antisense drug stabilized walking speed in a 54-patient pivotal trial; the FDA accepted Ionis's NDA for Priority Review with a target action date of September 22, 2026.